BENEFICIAL EFFECT OF XANTHOANGELOL, A CHALCONE COMPOUND FROM ANGELICA KEISKEI, ON LIPID METABOLISM IN STROKE‐PRONE SPONTANEOUSLY HYPERTENSIVE RATS
BENEFICIAL EFFECT OF XANTHOANGELOL, A CHALCONE COMPOUND FROM ANGELICA KEISKEI, ON LIPID METABOLISM IN STROKE‐PRONE SPONTANEOUSLY HYPERTENSIVE RATS
复制标题
DOI：
10.1111/j.1440-1681.2007.04578.x
复制
发表时间：
2007-03
影响因子：
2.9
通讯作者：
H. Ogawa;Y. Okada;T. Kamisako;K. Baba
中科院分区：
文献类型：
--
作者：
H. Ogawa;Y. Okada;T. Kamisako;K. Baba
最近，我们报道了当归提取物（从茎黄液中提取的乙酸乙酯提取物）中主要的查尔酮之一- 4 -羟基莪术素对卒中易发自发性高血压大鼠（SHRSP）具有降血压和脂质调节作用。在本研究中，我们分离了keiskei提取物中的另一种主要查尔酮——黄原酚，并研究了膳食黄原酚对SHRSP血压和脂质代谢的影响。2 6周龄雄性SHRSP饲喂含有0.02%或0.1%黄原酚（分别为0.02和0.10 Xan）的饲粮，为期7周，可自由使用饲粮和水。在整个实验期间，每天的食物摄入量、体重或收缩压没有显著变化。在两个实验组中，血清总胆固醇水平趋于降低（尽管不显著），这是由于低密度脂蛋白（LDL）部分胆固醇含量的剂量依赖性降低。这些结果表明，膳食中的黄酚可降低血清LDL水平。在肝脏中，在0.02和0.10 Xan组中，肝脏相对重量和总甘油三酯含量显著的剂量依赖性降低。此外，在0.10 Xan组中发现总胆固醇含量显著降低，这可能是由于除了肝脏重量减轻外，粪便胆固醇排泄量增加。4对肝脏中参与脂质代谢的蛋白质mRNA表达的研究表明，在0.10 Xan组中，过氧化物酶体增殖物激活受体(PPAR) α mRNA表达的显著增加与酰基辅酶a （CoA）合成酶和酰基辅酶a氧化酶mRNA表达的增加趋势相关，这可能至少在一定程度上导致了黄原angelol处理大鼠肝脏甘油三酯含量的降低。此外，在0.10 Xan组中LDL受体mRNA表达的显著增加可能是导致黄原酚处理大鼠血清LDL水平下降的原因，至少是部分原因。综上所述，饲粮中添加黄酚可降低SHRSP的血清LDL水平，降低肝脏中总胆固醇和甘油三酯含量。这些有益效果在食用含有0.10%黄原酚的饮食后更为有效。
1 Recently, we reported that 4‐hydroxyderricin, one of the major chalcones in Angelica keiskei extract (ethyl acetate extract from the yellow liquid of stems), exerted hypotensive and lipid regulatory actions in stroke‐prone spontaneously hypertensive rats (SHRSP). In the present study, we isolated xanthoangelol, another major chalcone in A. keiskei extract, and examined the effect of dietary xanthoangelol on blood pressure and lipid metabolism in SHRSP. 2 Six‐week‐old male SHRSP were fed diets containing 0.02% or 0.1% xanthoangelol (0.02 and 0.10 Xan, respectively) for 7 weeks, with free access to the diet and water. There were no significant changes in daily food intake, bodyweight or systolic blood pressure throughout the experimental period. Serum total cholesterol levels tended to decrease in the two experimental groups (albeit not significantly), which was due to a dose‐dependent decrease in the cholesterol content of the low‐density lipoprotein (LDL) fraction. These results suggest that dietary xanthoangelol decreases serum LDL levels. 3 In the liver, significant dose‐dependent decreases in relative liver liver weight and total triglyceride content were seen in the 0.02 and 0.10 Xan groups. In addition, a significant decrease in total cholesterol content was found in the 0.10 Xan group, which may be due to an elevation of faecal cholesterol excretion in addition to the decrease in liver weight. 4 Investigation of the hepatic mRNA expression of proteins involved in lipid metabolism indicated that there was a significant increase in peroxisome proliferator‐activated receptor (PPAR) α mRNA expression associated with the tendency for increases in acyl‐coenzyme A (CoA) synthetase and acyl‐CoA oxidase mRNA expression in the 0.10 Xan group, which may be responsible, at least in part, for the decrease in hepatic triglyceride content in the xanthoangelol‐treated rats. In additon, a significant increase in LDL receptor mRNA expression in the 0.10 Xan group may be responsible, at least in part, for the decrease in serum LDL levels in the xanthoangelol‐treated rats. 5 In conclusion, dietary xanthoangelol results in a reduction of serum LDL levels and decreases in total cholesterol and triglyceride contents in the liver of SHRSP. These beneficial effects are more effective following consumption of diet containing 0.10% xanthoangelol.